Departments of In Vivo Science, Merck Research Laboratories, West Point, PA 19486, USA.
J Cardiovasc Pharmacol. 2010 May;55(5):518-21. doi: 10.1097/FJC.0b013e3181d7665f.
Studies were conducted in human isolated coronary arteries to explore the vascular effects of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant and to compare its coronary vasoconstrictive potential to that of zolmitriptan. KCl precontracted coronary vessels were shown to relax to human alphaCGRP, with the CGRP-mediated vasorelaxation completely blocked with 30 microM telcagepant. In coronary vessels at basal tone, zolmitriptan caused a concentration-dependent contraction (pEC50 = 6.9 +/- 0.1; slope 0.94), with the greatest contraction obtained between 1 and 10 microM in most tissues. In contrast, telcagepant at concentrations up to 30 microM evoked no change in contractile tone. These findings suggest the potential for CGRP receptor antagonists to exert antimigraine efficacy in the absence of adverse effects on coronary tone.
研究人员在人体分离的冠状动脉中进行了研究,以探讨降钙素基因相关肽(CGRP)受体拮抗剂 telcagepant 的血管作用,并将其与佐米曲普坦的冠状动脉收缩潜力进行比较。结果表明,KC1 预收缩的冠状动脉对人αCGRP 产生松弛作用,30μM telcagepant 完全阻断 CGRP 介导的血管舒张作用。在基础张力的冠状动脉中,佐米曲普坦引起浓度依赖性收缩(pEC50=6.9±0.1;斜率 0.94),大多数组织中在 1 至 10μM 之间获得最大收缩。相比之下,高达 30μM 的 telcagepant 不会引起收缩张力的变化。这些发现表明,CGRP 受体拮抗剂有可能在不影响冠状动脉张力的情况下发挥抗偏头痛疗效。